Scarica l'app Stockscreener
1.49
3.47%
0.05
Dopo l'orario di chiusura:
1.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Precedente Chiudi:
$1.44
Aprire:
$1.43
Volume 24 ore:
915.35K
Relative Volume:
0.67
Capitalizzazione di mercato:
$422.10M
Reddito:
-
Utile/perdita netta:
$-125.04M
Rapporto P/E:
-1.8171
EPS:
-0.82
Flusso di cassa netto:
$-122.99M
1 W Prestazione:
-1.97%
1M Prestazione:
+9.16%
6M Prestazione:
-19.46%
1 anno Prestazione:
-53.29%
Intervallo 1D:
$1.43
$1.515
Intervallo di 1 settimana:
$1.34
$1.54
Portata 52W:
$1.01
$3.45
Erasca Inc Stock (ERAS) Company Profile
Nome
Erasca Inc
Settore
Industria
Telefono
(858) 465-6511
Indirizzo
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Confronta ERAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.49 | 430.60M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-26 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | Jefferies | Buy |
| 2024-03-11 | Iniziato | CapitalOne | Overweight |
| 2024-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-30 | Iniziato | Mizuho | Buy |
| 2023-02-24 | Iniziato | Goldman | Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Erasca Inc Borsa (ERAS) Ultime notizie
How Erasca Inc. stock performs during market volatilityAnalyst Grade Signals - Newser
What makes Erasca Inc. stock price move sharplyHigh Return Stock Alerts - Newser
Why Erasca Inc. stock attracts strong analyst attentionPredictable Return Stock Picks - Newser
Why Digital Turbine Inc. stock attracts strong analyst attentionMarket Beating Strategy - Newser
Why BRP Inc. stock attracts strong analyst attentionHigh Yield Stock Selection - Newser
Erasca, Inc. (NASDAQ:ERAS) Receives $4.57 Consensus Price Target from Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Invests $26,000 in NanoViricides, Inc. (NYSE:NNVC) - Defense World
58,547 Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Bought by Wealth Enhancement Advisory Services LLC - Defense World
Top Penny Stocks To Watch In July 2025 - simplywall.st
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail
Erasca Confirms Directors and Ratifies KPMG Appointment - TipRanks
ERAS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Ratio Analysis: Unpacking Northann Corp (NCL)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Erasca, Inc. (NASDAQ:ERAS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by California State Teachers Retirement System - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.12 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Squarepoint Ops LLC Takes Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Jane Street Group LLC Cuts Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Purchased by Ameriprise Financial Inc. - Defense World
Nuveen Asset Management LLC Acquires 72,121 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Stock Soars 10.73% on FDA Drug Clearance - AInvest
Erasca’s pan-KRAS inhibitor ERAS-4001 gains IND clearance - BioWorld MedTech
BNP Paribas Financial Markets Makes New Investment in Erasca, Inc. (NASDAQ:ERAS) - Defense World
FDA clears Erasca’s new cancer drug applications By Investing.com - Investing.com South Africa
Erasca Receives US FDA Approval of ERAS-4001 Investigational New Drug Application for Solid Tumors - marketscreener.com
FDA clears Erasca’s new cancer drug applications - Investing.com Australia
Erasca, Inc. Announces Ind Clearance for Potential First-In-Class and Best-In-Class Pan-Kras Inhibitor Eras-4001 - MarketScreener
Erasca (ERAS) Gains FDA Clearance for Innovative KRAS Inhibitor | ERAS Stock News - GuruFocus
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 - The Manila Times
Breakthrough: FDA Greenlights Novel Pan-KRAS Cancer Drug Targeting 2.2M Patients Worldwide - Stock Titan
ProShare Advisors LLC Raises Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Deutsche Bank AG Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Discover May 2025's Top Penny Stocks - simplywall.st
Bank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Precision Oncology Pioneer Erasca Sets Major Investor Presentations at Jefferies and Goldman Sachs Conferences - Stock Titan
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLC - Defense World
D. E. Shaw & Co. Inc. Has $927,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Northern Trust Corp Boosts Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of “Buy” by Analysts - Defense World
Erasca Inc (NASDAQ: ERAS) Could Pass $5 In One Year Stock Forecast - Stocksregister
Price T Rowe Associates Inc. MD Buys 10,899 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
HC Wainwright Has Positive Forecast for Erasca Q2 Earnings - Defense World
Erasca (ERAS) Target Price Adjusted by Guggenheim Analyst | ERAS Stock News - GuruFocus
FDA clears Erasca’s new cancer drug ERAS-0015 By Investing.com - Investing.com India
Erasca (ERAS) Advances RAS-Targeting Therapies with New Clinical Developments | ERAS Stock News - GuruFocus
Erasca Reports First Quarter 2025 Business Updates and Financial Results - The Manila Times
Erasca, Inc. Advances RAS-Targeting Pipeline with IND Clearances and Extended Cash Runway - Nasdaq
Erasca Advances Two Novel Cancer Drugs to Clinic, Secures 3-Year Cash Runway with $411M - Stock Titan
Erasca Inc Azioni (ERAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):